North America artificial intelligence (AI) in drug discovery market is expected to grow by 29.5% annually in the forecast period and reach $894.1 million by 2026 despite the COVID-19 impact.
Highlighted with 27 tables and 50 figures, this 117-page report “North America Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country.
Based on offering, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Software
• Service
Based on technology, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Deep Learning
• Supervised Learning
• Reinforcement Learning
• Unsupervised Learning
• Other Technologies
Based on drug type, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Large-molecule Drugs
• Small-molecular Drugs
Based on therapeutic area, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Other Therapeutic Areas
Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Information & Data Analysis
• Drug Design
• Drug Evaluation
• Clinical Trials
• Other Applications
Based on end user, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each of the aforementioned countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America AI in drug discovery market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Atomwise, Inc.
BenevolentAI
Berg LLC
Bioage
BIOAGE
Cloud Pharmaceuticals, Inc.
Cyclica
Deep Genomics
Envisagenics
Exscientia
Google
IBM Corporation
Insilico Medicine
Microsoft Corporation
Numedii, Inc.
Numerate
NVIDIA Corporation
Owkin, Inc.
Twoxar, Incorporated
Verge Genomics
Xtalpi, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
